OXS007417

OXS007417 is a **small molecule compound** developed as a differentiation therapy and cytostatic agent primarily targeting **acute myeloid leukemia (AML)**. It acts by **disrupting microtubule polymerization**, functioning as a **tubulin polymerization inhibitor**. In preclinical models, OXS007417 induces differentiation of AML cells with an EC50 of 48 nM and shows significant anti-leukemia activity in xenograft mouse models with delayed tumor growth. The compound demonstrates reasonable pharmacokinetics, including oral bioavailability, metabolic stability, and high cellular permeability, though it also exhibits high plasma protein binding. Early lead optimization efforts have aimed to improve solubility, metabolic stability, and off-target toxicity (such as hERG channel liability) while maintaining efficacy[1][3][5][7].